SHIONOGI and Ube Industries Entered into Strategic Research Collaboration for Novel Anti-RS Virus Drug Candidates
OSAKA, Japan and YAMAGUCHI, Japan. - Shionogi & Co., Ltd. (Head
Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter ?Shionogi?) and Ube
Industries, Ltd. (Head Office: Yamaguchi, Japan; President & Representative Director: Yuzuru
Yamamoto; hereafter ?Ube Industries?), today announced the conclusion of the strategic
research collaboration agreement for novel anti-RS (respiratory syncytial) virus drug
candidates.
Almost all people develop Respiratory Syncytial Virus (RSV) infection at least once before
reaching two years of age and are repeatedly infected with RSV throughout life. According to
the National Institute of Infectious Diseases, particularly from several weeks to several
months after birth, despite the presence of maternal antibody, RSV can cause serious
symptoms, mainly lower airway inflammation. Because there are currently no anti-RSV
products available, unmet medical need for safe and effective drugs to treat RSV infection is
high.
Shionogi and Ube Industries have strengths in the research and development of new
chemical entities of small molecules. Based on Shionogi?s drug discovery in the infectious
disease area and Ube Industries? drug design supported by organic synthesis capabilities, both
companies will produce a synergistic effect on SAR (Structure-Activity Relationship) study and
strive to provide best possible anti-RS virus drugs to patients as early as possible, combining
both companies? strengths to generate drug candidates. Both companies will aim to create an
innovation by collaborative research.
About Shionogi & Co., Ltd.
Shionogi's research and development efforts target infectious diseases as one of its priority
therapeutic areas, and Shionogi has positioned ?protecting people from the threat of infectious
diseases? as one of its core social missions. Shionogi strives constantly to bring forth innovative
drugs for the treatment of infectious diseases, to protect the health and well being of the many
patients we serve. For more details, please visit http://www.shionogi.co.jp
About Ube Industries, Ltd.
Ube Industries, Ltd. is a chemistry-focused company engaged in the areas of pharmaceuticals,
construction materials, machinery, energy and environment. In our pharmaceutical business,
we particularly focus on producing a new drug from our region with abundant technological
innovation and aim to contribute to better health for everyone. To allow us to contribute to
Press Release
2/2
progress of medication, we will continue our efforts to produce the seeds for new drugs based
on both ?Drug Discovery? through our own and collaboration research projects and
?Manufacture and Supply of API* and Intermediates?. For more detailed information on Ube
Industries, please visit our website. http://www.ube.co.jp
*: Active Pharmaceutical Ingredient
[Contact]
Corporate Communications, Shionogi & Co., Ltd.
Tel: +81-6-6209-7885